Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy

Table 3 Anti-MCV, anti-CCP, and IgM-RF at baseline and after 6 and 12 months of infliximab therapy

	Response 6 months	Baseline	6 months	Response 12 months	Baseline	12 months
Anti-MCV, U/mL	Responders (n = 11)	654 (89–2,918)	535 (56–3,000)	Responders (n = 15)	293 (61–2,918)	117^a (48–3,582)
	Nonresponders (n = 12)	307 (60–1,145)	227 (40–1,234)	Nonresponders (n = 8)	363 (60–1,145)	227 (47–1,500)
Anti-CCP, U/mL	Responders (n = 11)	1,402 (83–11,360)	1,300 (54–11,370)	Responders (n = 15)	1,246 (83–11,360)	837^b (48–12,640)
	Nonresponders (n = 12)	962 (130–4,232)	1,134 (74–2,392)	Nonresponders (n = 8)	1,169 (275–4,232)	1,331 (126–4,313)
IgM-RF, IU/mL	Responders (n = 11)	91.5 (10–424)	58 (10–216)	Responders (n = 15)	74.5 (9–781)	49.5^c (10–214)
	Nonresponders (n = 12)	205 (9–949)	133^c (10–367)	Nonresponders (n = 8)	283 (14–949)	152^c (35–463)

Values are expressed as median (range), and the nonparametric Wilcoxon signed rank test was used for paired comparisons of changes in anti-CCP and anti-MCV titres between responders and nonresponders. ^aP < 0.01 versus baseline; ^bP < 0.05 versus baseline; ^cP = 0.02 versus baseline. Anti-CCP, anti-cyclic citrullinated peptide antibody; anti-MCV, anti-mutated vimentin citrullinated antibody; RF, rheumatoid factor.

ISSN: 1478-6362